 |
Prospector
Profile
07.1645
|
| |
| Metabasis Therapeutics, Inc. |
NAICS |
541710 |
| 11119 North Torrey Pines Road
La Jolla, CA 92037 |
Description |
Biotechnology |
| (858) 587-2770 |
Employees |
127 |
| http://www.mbasis.com/ |
Revenue |
(mil) |
4.3860 |
| |
Income |
(mil) |
-33.2680 |
| |
Assets |
(mil) |
85.8550 |
| |
Liability |
(mil) |
17.7170 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Metabasis Therapeutics, Inc. had a net loss of $10.48 million on revenues of $2.65 million for the three months ended September 30, 2007, higher than the $8.41 million net loss on $1.06 million in revenues reported during the three months ended September 30, 2006. For the nine months ended September 30, 2007, the Company had a $30.92 million net loss, higher than the $23.52 million net loss incurred during the same period a year ago. As a result of its recurring losses, the Company's balance sheet at September 30, 2007, showed an accumulated deficit of $139.13 million.
|
| |
|
Intellectual Property:
As of February 22, 2007, the Company owned a total of 36 issued U.S. patents, 3 allowed U.S. applications and 27 pending U.S. applications. In foreign countries, the Company owned a total of 148 issued patents and 232 pending applications. It also co-owned 2 pending U.S. applications and 4 foreign granted applications. The Company held rights to a total of 4 in-licensed U.S. patents. The Company believes that it has a strong intellectual property position, including 16 issued U.S. patents, 3 allowed U.S. applications, 25 pending U.S. applications, 107 foreign issued patents and 227 foreign pending applications that relate to proprietary technologies and compounds used in its current business. The Company also relies on trade secrets, proprietary know-how and continuing innovation to develop and maintain competitive position. [SEC Filing 10-K 03-13-07]
|
| |
|
Description:
The biopharmaceutical company engages in the discovery, development, and commercialization of drugs for chronic diseases.
|
| |
|
Officers:
David F. Hale (Chair); Paul K. Laikind (Pres., CEO, Sec. & Dir.); John W. Beck (SVP, CFO & Treas.); Mark D. Erion (EVP, Chief Scientific Officer & Dir.); Daniel D. Burgess (Dir.); Luke B. Evnin (Dir.); Arnold L. Oronsky (Dir.); William R. Rohn (Dir.); Heinz Gschwend (Dir.)
|
| |
|
Auditor:
Ernst & Young LLP
|
| |
|
Securities:
Common Stock-Symbol MBRX; NasdaqGM;
30,657,305 common shares outstanding as of November 1, 2007.
|
| |
| |
| |
| return to main page |
|
|
